TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of  solid tumors as currently achieved for CD19+ hematological tumors.

Helsinki, FI
Size (employees)
8 (est)
Tilt Biotherapeutics was founded in 2013 and is headquartered in Helsinki, FI
Report incorrect company information

Tilt Biotherapeutics Office Locations

Tilt Biotherapeutics has an office in Helsinki
Helsinki, FI (HQ)
3 Haartmaninkatu
Show all (1)
Report incorrect company information

Tilt Biotherapeutics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$10.6 m

Latest funding size

$10.63 m

Time since last funding

2 years ago
Tilt Biotherapeutics's latest funding round in December 2016 was reported to be $10.6 m. In total, Tilt Biotherapeutics has raised $10.6 m
Show all financial metrics
Report incorrect company information

Tilt Biotherapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information